Erik Reinertsen, MD, PhD (@erikrtn) profile picture

Health & Life Sciences, Global BD @OpenAI

San Francisco, CA
Joined September 2014
Erik Reinertsen, MD, PhD retweeted
Healthcare is fragmented, and care teams do much of the work of holding it together. They track down records, re-enter information in various systems, and follow up so patients can get care. Today we’re sharing improvements to ChatGPT to help move care forward. 🧵
17
21
12
189
13,875
The @OpenAI Foundation is hiring a Head of AI for Alzheimer’s. This is a founding role within the Foundation’s life sciences program. You will work closely with the Head of Life Sciences and Curing Diseases to shape strategy, identify high-potential opportunities, and help deploy significant resources over time into organizations and initiatives that can materially accelerate progress. openaifoundation.org/careers…
8
14
103
5,076
Erik Reinertsen, MD, PhD retweeted
A new way to measure how AI agents handle the routine analyses of wet-lab science—BioBasicsBench. Developed with Ligo, a biotech company focused on enzyme design, the benchmark draws on 100 tasks from real experiments to test whether agents can interpret raw lab data, identify errors, and recognize when the evidence doesn’t support a conclusion. Accelerating biological research starts with getting the everyday work right. BioBasicsBench shows where models need to improve, and helps us track what those gains mean for scientific progress, biosafety, and biosecurity. openai.com/index/measuring-h…
827
279
333
3,765
921,462
Erik Reinertsen, MD, PhD retweeted
Starting today, eligible ChatGPT Pro and Business subscribers can claim up to $500 per month in API credits to build apps and agents.
643
807
967
9,202
2,135,419
Erik Reinertsen, MD, PhD retweeted
for my VC and startup friends: we’re hiring a VC Partnerships Manager at OpenAI. imo this is such a cool role and unique role. you’ll work hands-on with leading VCs and startups, helping builders turn ambitious ideas into some of the coolest, most impactful AI companies. if this sounds like you, take a look. and if someone comes to mind, please send this their way. openai.com/careers/vc-partne…
22
16
1
253
29,037
Erik Reinertsen, MD, PhD retweeted
Do you dream of the Codex UI at night too? Are you harassing and threatening your loved ones into trying it? Then you should probably apply to be a Codex Ambassador apply by Nov 1 - developers.openai.com/commun…
68
25
3
562
58,023
At @OpenAI we are hiring a Life Sciences Partnerships Lead to shape and execute OpenAI’s global life sciences partnership strategy. You will lead high-impact research, product, and platform partnerships across the life sciences ecosystem. Learn more and apply at openai.com/careers/business-…
12
25
1
267
21,965
Erik Reinertsen, MD, PhD retweeted
Replying to @gracexyzheng
@gracexyzheng and @xinjin have been wonderful friends and collaborators of the team since the very beginning. very excited for this work to be out and looking forward to even more!
GPT-Rosalind surfaced a new lead for drug discovery: could restoring cholesterol transport protect neurons from degeneration? DCTN1 is a gene linked to Perry syndrome, a rare neurodegenerative disorder. In mouse-brain data, disrupting it increased expression of genes involved in making cholesterol. GPT-Rosalind suggested a possible explanation: cholesterol may not be reaching where neurons need it. That gives scientists a specific mechanism to test and, if confirmed, a direction for developing new treatments for neurodegenerative disorders. With @perturbai_tx and @scrippsresearch, a team of thousands of GPT-Rosalind agents worked in parallel, connecting gene-expression results from millions of mouse brain cells with scientific literature in just 32 minutes. We’re now expanding this collaboration to identify new drug targets. openai.com/index/scaling-ai-…
7
12
2
222
52,763
Erik Reinertsen, MD, PhD retweeted
GPT-Rosalind surfaced a new lead for drug discovery: could restoring cholesterol transport protect neurons from degeneration? DCTN1 is a gene linked to Perry syndrome, a rare neurodegenerative disorder. In mouse-brain data, disrupting it increased expression of genes involved in making cholesterol. GPT-Rosalind suggested a possible explanation: cholesterol may not be reaching where neurons need it. That gives scientists a specific mechanism to test and, if confirmed, a direction for developing new treatments for neurodegenerative disorders. With @perturbai_tx and @scrippsresearch, a team of thousands of GPT-Rosalind agents worked in parallel, connecting gene-expression results from millions of mouse brain cells with scientific literature in just 32 minutes. We’re now expanding this collaboration to identify new drug targets. openai.com/index/scaling-ai-…
408
741
321
6,983
1,520,150
Erik Reinertsen, MD, PhD retweeted
We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner. Welcome @ashokaraj_ and team! openai.com/index/openai-to-a…
464
688
383
7,373
943,262
Erik Reinertsen, MD, PhD retweeted
More than 300 million people use ChatGPT for health and wellness questions each week. OpenAI’s Karan Singhal thinks that’s only the beginning. Karan joins a16z's Jay Rughani to explain how OpenAI is building health intelligence, the advantages of using generalized models for health applications, how AI could lower the cost of healthcare, and more. 00:00 Intro 01:00 How OpenAI is building health intelligence 07:57 A doctor in your pocket 14:20 Creating trust with users 19:44 Medical consensus and its 5–17 year lag 28:03 AI for mental health 30:59 How AI enables the healthcare ecosystem 38:21 A "move 37" for health 43:39 Driving down the cost of care 50:27 Procedural care and what's next YouTube: youtu.be/9n0MI4D7TCM @thekaransinghal @JayRughani
17
32
14
196
117,253
Erik Reinertsen, MD, PhD retweeted
Lung cancer rates are rising, particularly in people who are not smokers. When my sister Susan was diagnosed in 2023, we were shocked. When I read the news about Pope Leo XIV, I was again shocked. I hope this is a wake-up call for the world that anyone can get lung cancer, regardless of their history with smoking. More people die of lung cancer than of breast, prostate, and colon cancer combined, and we need a new approach to screening and treatment. lnkd.in/p/gNPH8wN8
10
11
1
81
11,900
Erik Reinertsen, MD, PhD retweeted
We're expanding access to GPT-Rosalind for academic research. The new Rosalind Academic Plan helps scientific labs bring AI into the work of understanding biology, exploring ideas, and deciding what to test next—with sponsored access for eligible labs at U.S. universities. Academic research starts with questions whose impact may take years to impact human health.
341
304
109
3,319
445,653
For a reader knowledgeable about clinical trials, the exercise in restraint is not to nitpick the obvious conceptual flaws -- ph3 already conditioned on success of prior preclinical, ph1, ph2 studies; LLM weights have bias from literature; "mathematical model" may imply formalism of MoA -- but to instead focus on the more interesting point: model alignment has a relationship with mechanism (including both what you are testing, and how the eval itself is constructed).
This is a slide from Terence Tao's 'Math 2.0' public lecture yesterday evening at Caltech. I am highly confident that, if the cure actually worked, almost any Stage 4 cancer patient would tell you that human comprehension of its mechanism is completely irrelevant to them.
2
13
1,264
Erik Reinertsen, MD, PhD retweeted
Earlier this year I was coding between cath lab cases - one hackathon later, I'm at Abridge. Now we're teaming up with Physician Side Gigs and @OpenAI to give physicians the same shot at HLTH. Bring a problem that bugs you every shift, and build it with top engineers from @AbridgeHQ and @OpenAI . Physicians only, no code needed, solo or with one colleague. Ideas due Oct 20. abridge.com/hlth2026
6
7
1
71
8,242
Erik Reinertsen, MD, PhD retweeted
Excited to introduce Onyx and announce our $8M seed round led by Dimension to build a virtual immune system! Onyx has always been a story of connection. The first connection was to my cofounder @amlakhan, a deeply curious technologist who I’ve been fortunate to call a friend for 19 years now. I've always said that working together was a cornerstone of starting Onyx, and it truly has been one of the best decisions I've ever made. Connection is also at the heart of what Onyx does. We believe AI is key to making biological complexity tractable, ultimately transforming life sciences into an engineering discipline. But that requires the right data. AI performance compounds with context, and richer biological context comes from more connected data. In biology, such context is often missing: molecular data, clinical history, and change over time are typically captured in isolated fragments. Onyx provides the substrate that connects them, pairing genomics, transcriptomics, proteomics, and metabolomics with rich clinical histories. By studying these layers together in people over time, our data platform traces how real human biology changes in response to infection, inflammation, and treatment. Seeing how these trajectories differ across people brings us closer to understanding what drives disease—and to developing precision medicines that work better for real people. Yet connecting data is only possible because of the people who have connected with our mission. Nearly a thousand members have already joined our research studies. They are more than research participants: they are difference-makers transforming how we understand some of humanity’s most complex and chronic diseases. I always say that our work is for people, but the truth is that people make our work possible. That connection comes full circle, and at Onyx, people will always come first. Finally, as we raised our oversubscribed round, we sought more than just business partners. We wanted investors we felt a true connection to—not merely sources of capital, but co-conspirators in creating meaningful change. To that end, we feel incredibly fortunate to have joined forces with @_DimensionCap, @haystackvc, @refactor, @standard_vc, @robotventures, and many more. Now back to building!
Today we're introducing Onyx, a research collective building a virtual immune system: a model of how real people respond to infection, inflammation, and treatment. We're launching with an $8M seed round led by Dimension Capital. onyx.bio/news/introducing-on…
21
27
8
112
20,076
Erik Reinertsen, MD, PhD retweeted
Your next meeting comes with a note-taker who can help with the follow-up. The Meetings plugin takes notes for you and saves a personalized summary and next steps in ChatGPT Space, based on what ChatGPT knows about you and the work you’ve done together. Keep notes private or share them with your team, then ask ChatGPT to update a project plan or draft a follow-up. Available in beta for Pro and Business users in the ChatGPT desktop app on macOS. Enterprise is coming soon. Download the desktop app, then search for “Meetings” in the plugin directory. chatgpt.com/download/
338
358
303
5,525
1,296,685
Erik Reinertsen, MD, PhD retweeted
Replying to @petergostev
Counting only equivalent API cost would show only half the picture IMO.
49
19
8
526
593,701
Erik Reinertsen, MD, PhD retweeted
Scientific research is scattered. @OpenAI's Rosalind Workbench allows life science researchers to analyze data, inspect evidence, and review outputs in one place. tinyurl.com/2b4c4jwp
6
3
1
19
8,367
Erik Reinertsen, MD, PhD retweeted
The life sciences FDE team at OpenAI is hiring! If you’re interested, send me your resume and we’ll set up an interview if it seems like there’s a fit!
37
38
6
923
144,245